This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yasuoka, A. Articles by Shimada, K. Search for Related Content PubMed PubMed Citation Articles by Yasuoka, A. Articles by Shimada, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Mar 1995, 720-724, Vol 39, No. 3
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451)

A Yasuoka, S Oka, K Komuro, H Shimizu, K Kitada, Y Nakamura, S Shibahara, T Takeuchi, S Kondo and K Shimada
Department of Infectious Diseases, University of Tokyo, Japan.

Benanomicin A (BNM-A) has antimycotic activities via binding to mannan in the cell walls of fungi. Anti-Pneumocystis carinii activity of the agent was examined in the P. carinii-infected BALB/c nu/nu female mouse model because P. carinii also possesses mannan in the membranes. The infected mice were treated with intraperitoneal injections of six doses of BNM-A (1, 2.5, 5, 10, 30, and 100 mg/kg of body weight), 4 mg of pentamidine isethionate per kg, 100 mg of sulfamethoxazole per kg combined with 20 mg of trimethoprim per kg (co-trimoxazole), or saline for 21 days. Each dosage group consisted of 10 mice. During treatment, five mice in the control group (saline) died, whereas 8 to 10 mice in all treatment groups survived. Almost the same efficacies were obtained for the groups treated with 5 mg or more and 10 mg or more of BNM-A per kg regarding the weight and number, respectively, of cysts found in the lungs as were obtained for the groups treated with pentamidine isethionate and co-trimoxazole. Overall, a dose of 10 mg of BNM-A per kg was effective against P. carinii pneumonia infection in the mice. Thus, BNM-A is a good candidate for a novel treatment for P. carinii pneumonia as a compound with a new mechanism of action against P. carinii.

This article has been cited by other articles:

• Disney, M. D., Stephenson, R., Wright, T. W., Haidaris, C. G., Turner, D. H., Gigliotti, F. (2005). Activity of Hoechst 33258 against Pneumocystis carinii f. sp. muris, Candida albicans, and Candida dubliniensis. Antimicrob. Agents Chemother. 49: 1326-1330 [Abstract] [Full Text]